Last reviewed · How we verify
CB307
At a glance
| Generic name | CB307 |
|---|---|
| Sponsor | Crescendo Biologics Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions (PHASE1)
- Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CB307 CI brief — competitive landscape report
- CB307 updates RSS · CI watch RSS
- Crescendo Biologics Ltd. portfolio CI